Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis
暂无分享,去创建一个
Jeffrey A. Cohen | H. Atkins | A. Bar-Or | M. Freedman | J. Galipeau | M. Boivin | P. Darlington | L. Solchaga | C. Renoux | M. François | J. Cohen
[1] Keith A. Johnson,et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy , 2010, Annals of neurology.
[2] H. Atkins,et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group , 2010, Multiple sclerosis.
[3] Jiuhong Kang,et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis , 2009, Nature Immunology.
[4] Zhenping Chen,et al. Fetal BM‐derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells , 2009, European journal of immunology.
[5] P. Duquette,et al. Preferential recruitment of interferon‐γ–expressing TH17 cells in multiple sclerosis , 2009, Annals of neurology.
[6] S. Miller,et al. Human bone marrow‐derived mesenchymal stem cells induce Th2‐polarized immune response and promote endogenous repair in animal models of multiple sclerosis , 2009, Glia.
[7] K. Schäkel,et al. Mesenchymal stem cells efficiently inhibit the proinflammatory properties of 6-sulfo LacNAc dendritic cells , 2009, Haematologica.
[8] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[9] A. Uccelli,et al. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks , 2009, Bone Marrow Transplantation.
[10] D. Wraith,et al. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration , 2008, Neuroscience Letters.
[11] D. Karussis,et al. The potential use of stem cells in multiple sclerosis: An overview of the preclinical experience , 2008, Clinical Neurology and Neurosurgery.
[12] K. Bendtzen,et al. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis , 2008, Immunology.
[13] A. Uccelli,et al. Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.
[14] C. Crescioli,et al. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment , 2008, Journal of Neuroimmunology.
[15] J. Trojanowski,et al. Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasal Degeneration but Not in Other Tauopathies , 2008, Journal of neuropathology and experimental neurology.
[16] R. Zhao,et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell Stem Cell.
[17] D. Arnold,et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. , 2007, Archives of neurology.
[18] Joylee Wu,et al. The National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data Set , 2007, Alzheimer disease and associated disorders.
[19] A. Uccelli,et al. Mesenchymal stem cells: a new strategy for immunosuppression? , 2007, Trends in immunology.
[20] Sergio Romagnani,et al. Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .
[21] Marvin Bergsneider,et al. Development of Guidelines for Idiopathic Normal-pressure Hydrocephalus: Introduction , 2005, Neurosurgery.
[22] G. Mancardi,et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.
[23] O. Koç,et al. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. , 2005, Experimental hematology.
[24] V. Goldberg,et al. FGF‐2 enhances the mitotic and chondrogenic potentials of human adult bone marrow‐derived mesenchymal stem cells , 2005, Journal of cellular physiology.
[25] M. Pittenger,et al. Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.
[26] M. Poca,et al. Is the placement of shunts in patients with idiopathic normal-pressure hydrocephalus worth the risk? Results of a study based on continuous monitoring of intracranial pressure. , 2004, Journal of neurosurgery.
[27] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[28] J. Trojanowski,et al. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases , 2002, Annals of neurology.
[29] R. Gur,et al. Neuropsychological functioning in elderly patients with schizophrenia and Alzheimer's disease , 2002, Schizophrenia Research.
[30] A. Caplan,et al. Dilution of human mesenchymal stem cells with dermal fibroblasts and the effects on in vitro and in vivo osteochondrogenesis , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.
[31] B. Stegmayr,et al. Three-year survival and functional outcome of patients with idiopathic adult hydrocephalus syndrome , 2000, Neurology.
[32] A. Kluger,et al. Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response , 2000, Journal of neurology, neurosurgery, and psychiatry.
[33] M. Pittenger,et al. Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.
[34] F. Schmitt,et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. , 1999, Journal of neuropathology and experimental neurology.
[35] H. Braak,et al. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.
[36] W. Halliday,et al. Neuropathological Changes in Chronic Adult Hydrocephalus: Cortical Biopsies and Autopsy Findings , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[37] M. Goedert,et al. Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404 , 1994, Journal of neuroscience research.
[38] O Ouchterlony,et al. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. , 1983, Journal of immunological methods.
[39] L. Steinman. Mixed results with modulation of TH-17 cells in human autoimmune diseases , 2010, Nature Immunology.
[40] Sergio Romagnani,et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. , 2006, Stem cells.
[41] A. Marmarou,et al. Three-year outcome of shunted idiopathic NPH patients. , 2005, Acta neurochirurgica. Supplement.
[42] R. Doms,et al. Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. , 2003, The Journal of biological chemistry.
[43] G. Waldemar,et al. Shunting Effects in Patients with Idiopathic Normal Pressure Hydrocephalus; Correlation with Cerebral and Leptomeningeal Biopsy Findings , 1999, Acta Neurochirurgica.
[44] K. M. Gill,et al. Clinical Gait Assessment in the Neurologically Impaired , 1984 .